NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=151997&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Fortrea Holdings Inc. (NASDAQ:FTRE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortrea-holdings-inc-lawsuit-submission-form?prid=151987&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Strategy Incorporated (NASDAQ:MSTR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/strategy-incorporated-lawsuit-submission-form?prid=151995&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=151989&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Bitfarms Ltd. (NASDAQ:BITF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bitfarms-ltd-lawsuit-submission-form?prid=151992&wire=1&utm_campaign=2 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=151981&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Krispy Kreme, Inc. (NASDAQ:DNUT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/krispy-kreme-inc-lawsuit-submission-form?prid=151982&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=151980&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.

Investors were hopeful for signs that the two might reconcile after Tesla suffered its worst single-day drop in more than four years, though President Trump said Friday he has no interest in a call with CEO Elon Musk.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cable One, Inc. (“Cable One” or the “Company”) (NYSE: CABO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Take-Two Interactive rides a 17% bookings surge as demand for Grand Theft Auto, NBA 2K and new titles fuels its growth outlook.

Volaris witnesses a lower May load factor as capacity outpaced demand, despite carrying 2.5 million passengers, up 4.2% year over year.

FuelCell Energy, Inc. (NASDAQ:FCEL ) Q2 2025 Earnings Conference Call June 6, 2025 10:00 AM ET Company Participants Jason B. Few - President, CEO & Director Michael S.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.